Id: acc4509
Group: 1sens
Protein: AKT
Gene Symbol: AKT1
Protein Id: P31749
Protein Name: AKT1_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Pancreatic Cancer
Disease Subtype:
Disease Cellline:
Disease Info:
Drug: Apatinib + APS
Drug Info: "Apatinib is a targeted anti - tumor drug | APS may refer to various substances, and its specific properties depend on the context, here it is combined with Apatinib for potential therapeutic use. "
Effect: modulate
Effect Info: "Apatinib has an inhibitory effect on pancreatic cancer cells. Astragalus polysaccharide can significantly enhance the anti - tumor effect of apatinib by further reducing the phosphorylation levels of AKT and ERK (i.e., reducing the active states of these proteins) and decreasing the expression of MMP - 9. "
Note: drug comb
Score: 4.0
Pubmed(PMID): 29785118
Sentence Index:
Sentence:

Sequence & Structure:

MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed metastatic prostate cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast neoplasm ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed triple-negative breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Completed breast cancer ClinicalTrials
AKT1 IPATASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Terminated breast cancer ClinicalTrials
AKT1 AFURESERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting breast cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Recruiting prostate cancer ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 3 Active, not recruiting prostate cancer ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed hepatocellular carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed head and neck squamous cell carcinoma ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Active, not recruiting neoplasm of mature B-cells ClinicalTrials
AKT1 UPROSERTIB Serine/threonine-protein kinase AKT inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Active, not recruiting adenocarcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Terminated breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed adenosquamous lung carcinoma ClinicalTrials
AKT1 UPROSERTIB Serine/threonine-protein kinase AKT inhibitor 2 Completed breast carcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed bronchoalveolar adenocarcinoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Completed diffuse large B-cell lymphoma ClinicalTrials
AKT1 MK-2206 Serine/threonine-protein kinase AKT inhibitor 2 Terminated diffuse large B-cell lymphoma ClinicalTrials
AKT1 CAPIVASERTIB Serine/threonine-protein kinase AKT inhibitor 2 Terminated gastric adenocarcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

AKT1-Ser124
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Ser126
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Ser129
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1-Thr448
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
AKT1-Thr450
Cancer Intensity
BRCA
COAD -0.936
HGSC -1.526
ccRCC 0.252
GBM 0.594
HNSC
LUAD 0.617
LUSC
non_ccRCC
PDAC
UCEC 0.999
AKT1-Tyr315
Cancer Intensity
BRCA 0.788
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.125
LUSC 0.336
non_ccRCC
PDAC
UCEC
AKT1S1-Ser183
Cancer Intensity
BRCA 1.667
COAD 0.891
HGSC 0.725
ccRCC -1.189
GBM 0.792
HNSC 0.064
LUAD -0.194
LUSC -0.266
non_ccRCC -1.722
PDAC -0.879
UCEC 0.11
AKT1S1-Ser202
Cancer Intensity
BRCA -0.344
COAD -0.013
HGSC -2.725
ccRCC -0.093
GBM -0.249
HNSC 0.707
LUAD 0.324
LUSC 0.615
non_ccRCC 0.322
PDAC 0.379
UCEC 1.076
AKT1S1-Ser203
Cancer Intensity
BRCA -0.189
COAD 0.095
HGSC -2.902
ccRCC 0.277
GBM 0.142
HNSC 0.479
LUAD 0.265
LUSC 0.603
non_ccRCC 0.04
PDAC 0.419
UCEC 0.771
AKT1S1-Ser211
Cancer Intensity
BRCA -1.13
COAD 0.333
HGSC -2.178
ccRCC 0.627
GBM 0.09
HNSC 1.177
LUAD -0.47
LUSC 0.383
non_ccRCC
PDAC 0.715
UCEC 0.451
AKT1S1-Ser212
Cancer Intensity
BRCA -1.05
COAD 0.546
HGSC -2.08
ccRCC -0.197
GBM 0.641
HNSC 1.003
LUAD -0.628
LUSC 0.311
non_ccRCC
PDAC 0.36
UCEC 1.094
AKT1S1-Ser247
Cancer Intensity
BRCA
COAD -1.124
HGSC
ccRCC
GBM 0.791
HNSC 0.334
LUAD
LUSC
non_ccRCC
PDAC
UCEC
AKT1S1-Ser88
Cancer Intensity
BRCA -1.265
COAD -0.583
HGSC
ccRCC -0.267
GBM 0.344
HNSC 2.36
LUAD -0.052
LUSC 0.649
non_ccRCC -0.088
PDAC -0.187
UCEC -0.912
AKT1S1-Ser92
Cancer Intensity
BRCA -1.122
COAD -0.689
HGSC
ccRCC 0.068
GBM -0.037
HNSC 2.235
LUAD 0.28
LUSC 0.221
non_ccRCC -0.997
PDAC 0.777
UCEC -0.735
AKT1S1-Thr198
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.647
GBM
HNSC
LUAD -0.505
LUSC
non_ccRCC
PDAC
UCEC 1.152
AKT1S1-Thr246
Cancer Intensity
BRCA
COAD -0.468
HGSC 0.953
ccRCC
GBM -1.179
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.694
AKT1S1-Thr90
Cancer Intensity
BRCA
COAD 0.347
HGSC -1.784
ccRCC 0.431
GBM
HNSC 0.542
LUAD 0.465
LUSC
non_ccRCC
PDAC
UCEC
AKT1S1-Thr97
Cancer Intensity
BRCA 1.061
COAD -1.872
HGSC
ccRCC 0.814
GBM -0.592
HNSC 0.541
LUAD 0.201
LUSC
non_ccRCC
PDAC
UCEC -0.152

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Laryngeal cancer Phosphorylation 23886414
- - D Sepsis Acetylation 37211747
- - D Oral squamous cell carcinoma Phosphorylation 23723304
- - D Myelodysplasia Phosphorylation 12529294
- - D Glioma/adult gliomas Phosphorylation 12839945
- - P Cancer SUMOylation 23884910
- - P Acute monocytic leukemia Phosphorylation 24422998
S - P Colon cancer/carcinoma Phosphorylation 24464560
- - P Glioblastoma Phosphorylation 23262078
- - P Embryonal central nervous system tumor Phosphorylation 16230398
- - P Brain cancer Phosphorylation 12388552
- - U Endometrial cancer Phosphorylation 12888921
- - U Thyroid cancer Phosphorylation 12788904
- - U Cervical cancer/carcinoma Phosphorylation 10853013
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 10853013
- - U Marek's disease Phosphorylation 35795905
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 23785446
- - U Gastric cancer Phosphorylation 23898095
- - U Renal cell carcinoma Phosphorylation 34257606
- - U Hepatocellular carcinoma Acetylation 31842909
- - U Pancreatic cancer Phosphorylation 31765735
- - U Colorectal cancer Phosphorylation 35110545
- - U Gastric cancer Phosphorylation 36604355
- - U Urothelial bladder cancer Phosphorylation 35691981
- - U Epithelial ovarian cancer Phosphorylation 35105347
- - U Tongue cancer Phosphorylation 37132640
- - U Papillary thyroid cancer Acetylation 37696385

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: